

## ORIGINAL ARTICLE

# A subset of metastatic pancreatic ductal adenocarcinomas depends quantitatively on oncogenic Kras/Mek/Erk-induced hyperactive mTOR signalling

Bo Kong,<sup>1</sup> Weiwei Wu,<sup>1</sup> Tao Cheng,<sup>1</sup> Anna Melissa Schlitter,<sup>2</sup> Chengjia Qian,<sup>1</sup> Philipp Bruns,<sup>1,3</sup> Ziyang Jian,<sup>1</sup> Carsten Jäger,<sup>1</sup> Ivonne Regel,<sup>1</sup> Susanne Raulefs,<sup>1</sup> Nora Behler,<sup>1</sup> Martin Irmeler,<sup>4</sup> Johannes Beckers,<sup>4,5,6</sup> Helmut Friess,<sup>1</sup> Mert Erkan,<sup>7</sup> Jens T Siveke,<sup>8</sup> Andrea Tannapfel,<sup>9</sup> Stephan A Hahn,<sup>10</sup> Fabian J Theis,<sup>3</sup> Irene Esposito,<sup>2</sup> Jörg Kleff,<sup>1</sup> Christoph W Michalski<sup>11</sup>

► Additional material is published online only. To view please visit the journal online (<http://dx.doi.org/10.1136/gutjnl-2014-307616>).

For numbered affiliations see end of article.

**Correspondence to**

Dr Christoph W Michalski, Department of Surgery, University of Heidelberg, Im Neuenheimer Feld 110, Heidelberg 69120, Germany; [cwmichalski@gmail.com](mailto:cwmichalski@gmail.com)

JK and CWM contributed equally.

Received 7 May 2014

Revised 7 December 2014

Accepted 22 December 2014

**ABSTRACT**

**Objective** Oncogenic Kras-activated robust Mek/Erk signals phosphorylate the tuberous sclerosis complex (Tsc) and deactivates mammalian target of rapamycin (mTOR) suppression in pancreatic ductal adenocarcinoma (PDAC); however, Mek and mTOR inhibitors alone have demonstrated minimal clinical antitumor activity.

**Design** We generated transgenic mouse models in which mTOR was hyperactivated either through the Kras/Mek/Erk cascade, by loss of Pten or through Tsc1 haploinsufficiency. Primary cancer cells were isolated from mouse tumours. Oncogenic signalling was assessed in vitro and in vivo, with and without single or multiple targeted molecule inhibition. Transcriptional profiling was used to identify biomarkers predictive of the underlying pathway alterations and of therapeutic response. Results from the preclinical models were confirmed on human material.

**Results** Reduction of Tsc1 function facilitated activation of Kras/Mek/Erk-mediated mTOR signalling, which promoted the development of metastatic PDACs. Single inhibition of mTOR or Mek elicited strong feedback activation of Erk or Akt, respectively. Only dual inhibition of Mek and PI3K reduced mTOR activity and effectively induced cancer cell apoptosis. Analysis of downstream targets demonstrated that oncogenic activity of the Mek/Erk/Tsc/mTOR axis relied on Aldh1a3 function. Moreover, in clinical PDAC samples, ALDH1A3 specifically labelled an aggressive subtype.

**Conclusions** These results advance our understanding of Mek/Erk-driven mTOR activation and its downstream targets in PDAC, and provide a mechanistic rationale for effective therapeutic matching for Aldh1a3-positive PDACs.

**INTRODUCTION**

Despite enormous progress in the understanding of underlying molecular biology, pancreatic ductal adenocarcinoma (PDAC) remains a fatal, treatment-refractory disease. Although it is homogeneous (almost uniformly carries mutant, oncogenic Kras), there is considerable heterogeneity in clinical outcomes. Recently, these findings have been attributed to various levels of oncogene addiction<sup>1</sup> to context

**Significance of this study****What is already known on this subject?**

- The majority of human pancreatic ductal adenocarcinomas (PDACs) with oncogenic KRAS mutations and active mammalian target of rapamycin (mTOR) signalling do not respond to mTOR inhibition.
- Though oncogenic KRAS can activate mTOR through MEK/ERK or PI3K/AKT, genetic changes along the PI3K/AKT pathway have been proposed as biomarkers for mTOR inhibition.
- The tuberous sclerosis complex is required to relay signals from MEK/ERK and/or PI3K/AKT to mTOR.

**What are the new findings?**

- Tuberous sclerosis complex 1 is a dose-dependent tumour suppressor which facilitates the oncogenic Kras-mediated Mek/Erk-to-mTOR signal to drive metastatic PDACs.
- Dual inhibition of Mek and PI3K effectively decreases oncogenic Kras/Mek/Erk-induced mTOR (hyper)activity.
- The oncogenic activity of the Mek/Erk/mTOR axis relies on Aldh1a3, which also labels an aggressive subtype of human PDAC.
- Genetically engineered mouse models can be used to specify a PDAC subset and its respective biomarker, Aldh1a3.

**How might it impact clinical practice in the foreseeable future?**

- Therapeutic matching according to ALDH1A3 levels and dual MEK/PI3K inhibition in this subset of patients is a reasonable strategy for testing in a clinical setting.
- Future mTOR inhibition studies should take the mTOR activation pattern into consideration to predict putative inhibition-induced counteractive feedback responses.

dependency of the oncogenic potential of Kras and to the complex signalling network dynamics activated by mutated Kras.<sup>2</sup>

**To cite:** Kong B, Wu W, Cheng T, *et al.* Gut Published Online First: [please include Day Month Year] doi:10.1136/gutjnl-2014-307616

Though few PDACs rely on PI3K/Akt as their oncogenic backbone,<sup>3,4</sup> robust Mek/Erk activity seems to be the major driver of pancreatic oncogenesis and is a requirement for epithelial transformation.<sup>5,6</sup> Deactivation of tuberous sclerosis complex (Tsc) function is one of the major effects of Mek/Erk activation. The Tsc is also where the Mek/Erk and PI3K/Akt pathways converge and has been shown to be a quantitative tumour suppressor in other tumour entities.<sup>7,8</sup> Loss or impaired activity of Tsc decreases mammalian target of rapamycin (mTOR) inhibition, leading to its activation (also in PDAC<sup>9</sup>). Decreasing mTOR activity as one of the proliferation master switches was, therefore, thought to have a potentially therapeutic effect in PDAC. Clinical trials, however, have largely failed to demonstrate any benefit of direct mTOR inhibition.<sup>10</sup> There are a number of possible explanations for these findings. Single effector inhibition may only be modestly active as Kras activates multiple parallel networks.<sup>2</sup> Negative feedback signalling<sup>11</sup> or molecular heterogeneity of PDAC below the level of oncogenic Kras (eg, coexisting genetic alternations along the PI3K/Akt pathway) may be other contributing factors. The latter hypothesis is supported by the activity of single molecule inhibition in small groups of patients.<sup>12,13</sup> Consequently, biomarkers defining particular subsets of patients that are more likely to respond to a specific treatment must be identified. Understanding clinical failure of mTOR inhibition also necessitates an understanding of Tsc-mediated mTOR hyperactivation patterns in vivo.

Because Tsc1-haploinsufficiency has been shown to induce oncogenic Kras-driven cancer in the lungs,<sup>7</sup> we hypothesised that TSC might be downregulated in a subset of PDACs and a reduction of Tsc function may facilitate oncogenic Kras-driven mTOR activation in PDAC. Using transgenic mouse models and in vitro signalling analyses, we dissected Mek/Erk/Tsc-driven mTOR signalling in PDAC. Further analyses identified biomarkers predictive of response to combinatorial inhibition of pathways upstream of mTOR. These data lay the foundation for transcriptional biomarker-based treatment schemes aiming to achieve a persistent decrease in mTOR hyperactivation in PDAC patient subsets.

## METHODS

### Patient material and tissue collection

We obtained PDAC tissues from patients who had undergone pancreatic resections. All sample diagnoses were confirmed histologically. Samples were either snap-frozen in liquid nitrogen or were fixed in paraformaldehyde solution for 24 h and subsequently paraffin-embedded for histological analysis. The use of tissue for this study was approved by the local Ethics Committee and written informed consent was obtained from patients prior to surgery (Department of Surgery, Klinikum rechts der Isar, Technical University Munich; resections on patients with PDAC were performed between 2007 and 2010). Detailed clinical and pathological data were obtained from each patient. Patients who survived less than 2 months postsurgery were excluded from the survival analysis in order to rule out surgery-related mortality. Donor pancreases were obtained through an organ donor programme from previously healthy individuals. Tissue slides from human xenograft PDAC were processed, as previously reported.<sup>14,15</sup>

### Mouse lines

Mice containing floxed allele of Pten (006440), Tsc1 (005680), p53 (008462) or the Loxp-STOP-Loxp-Kras<sup>G12D</sup> (LSL-Kras<sup>G12D</sup>; 008179) were obtained from The Jackson Laboratory (Bar Harbor, Maine, USA). The pancreas-specific Cre recombinase

line Ptf1a<sup>Cre/+</sup> (also known as p48<sup>Cre/+</sup>) was from Roland M. Schmid and JTS (Department of Gastroenterology, TU Munich). The wild type (WT; C57BL/6J) and the BALB/c nude mice were obtained from Charles River Laboratory (Sulzfeld, Germany).

### Mouse breeding

Mouse breeding was performed and husbandry was maintained at the specific pathogen-free mouse facility at the Technical University of Munich. The compound transgenic mice were maintained on a mixed background. All mouse experiments and procedures were approved by the Institutional Animal Care and Use Committees of the Technical University of Munich. All procedures were in accordance with the Office of Laboratory Animal Welfare and the German Federal Animal Protection Laws.

### Primary cell isolation

Freshly dissected sterile tumour tissues were washed twice with ice-cold PBS, cut into small cubes (approximately 1 mm) and dispensed into 5 mL of complete medium containing collagenase (1.2 mg/mL). The resulting solution (mixed with tissue blocks) was incubated at 37°C for 0.5 h. After centrifugation at 300 rpm for 5 min, the small tissue blocks were washed twice with collagenase-free medium, followed by incubation at 37°C with medium containing collagenase for an additional 0.5 h. After passing the undigested tissue blocks through a 100 µm nylon mesh, cell suspensions were obtained. These cell suspensions were washed two times with complete medium and seeded into a 10 cm<sup>2</sup> dish.

### Further materials and methods

A detailed materials and methods section is provided as a supplement to this manuscript.

### Statistical analysis

Either GraphPad Prism V5 Software (GraphPad, San Diego, California, USA) or IBM SPSS V.19 Software (Statistical Package for the Social Sciences, IBM, New York, USA) was used for the statistical analysis.  $\chi^2$  or Fisher's exact tests were used to compare distribution of categorical factors between the different groups. All experiments were repeated at least three times. Unless otherwise stated, an unpaired Student t test was used for comparisons of two groups. Statistical significance was set at  $p < 0.05$ . Results are expressed as mean  $\pm$  SD unless indicated otherwise.

## RESULTS

### Tsc1 (haplo)insufficiency facilitates oncogenic Kras/Mek/Erk signalling to mTOR, promoting development of metastatic PDACs

As Tsc is required to relay both Mek/Erk and PI3K/Akt signals to mTOR, and as oncogenic Kras can activate both of these pathways in PDAC, we first assessed mTOR phosphorylation and then analysed Tsc expression. Consistent with published data,<sup>9</sup> 89% (39/44) of PDAC samples were p-mTOR<sup>ser2448</sup>-positive, demonstrating active mTOR signalling in the majority of cases (see online supplementary figure S1A). Also in line with these findings, *TSC1* and *TSC2* mRNA were downregulated compared with the normal/healthy pancreas (see online supplementary figure S1B). This suggested that the TSC facilitates mTOR activation in human PDAC; *TSC2* mutations have even been reported in a subset of human PDACs.<sup>16</sup> As complete loss of *TSC1* or *TSC2* is rare,<sup>16</sup> the majority of the following experiments are

based on mouse models with *Tsc1* haploinsufficiency. The well-described knock-in oncogenic *Kras* (LSL-*Kras*<sup>G12D/+</sup>), expressed specifically in the pancreas under the control of the *Ptf1a* promoter (*Ptf1a*<sup>Cre/+</sup>), was used as the PDAC backbone.<sup>17</sup> *Ptf1a*<sup>Cre/+</sup>; LSL-*Kras*<sup>G12D/+</sup> are referred to as *Kras*<sup>G12D/+</sup>. Unless otherwise stated, all animals were followed up for up to 1.5 years or sacrificed for histological analysis if they showed any sign of disease.

Median survival of a *Kras*<sup>G12D/+</sup>; *Tsc1*<sup>-/+</sup> mice cohort (n=22) was 328 days, which was significantly shorter than the *Kras*<sup>G12D/+</sup> mice (412 days; n=34, [figure 1A](#)). Detailed histological reports were available for 20 *Kras*<sup>G12D/+</sup>; *Tsc1*<sup>-/+</sup> mice. Ninety-five per cent (19/20) developed invasive PDAC and 68% of those (13/19) developed metastases ([figure 1B–D](#)) affecting the liver (13/13), lungs (6/13), and kidneys (3/13, [figure 1E](#)). Detailed histological reports were available for 30 *Kras*<sup>G12D/+</sup> mice. In contrast, a much smaller percentage of *Kras*<sup>G12D/+</sup> mice (33%, 10/30) developed PDAC and the metastatic rate was low (20%, 2/10, [figure 1B](#)). Histological analysis of *Kras*<sup>G12D/+</sup>; *Tsc1*<sup>-/+</sup> mice tumours showed invasive PDAC with a focal sarcomatoid-like pattern (eg, dedifferentiation, [figure 1D](#)) and focal papillary growth patterns in a few cases. The majority of tumours displayed diffuse and large necrotic areas ([figure 1D](#)) where many duct-like structures from pre-existing cancer cells were preserved. The distribution of the necrotic regions followed an eccentric pattern and the central necrotic region was surrounded by vascularised tumour tissues.

To confirm robust downstream activation of mTOR and S6, phosphorylation stainings were performed. *Kras*<sup>G12D/+</sup>; *Tsc1*<sup>-/+</sup> tumours were p-mTOR<sup>Ser2448</sup>-positive and p-S6<sup>Ser235/236</sup>-positive (6/6, [figure 1F](#)). Differentiation of the origin of the upstream signal (eg, *Kras* activation of either Mek/Erk or PI3K/Akt) in this particular setting was achieved with p-Erk1/2<sup>Thr202/Tyr204</sup> and p-Akt<sup>Ser473</sup> stainings, demonstrating that six out of six *Kras*<sup>G12D/+</sup>; *Tsc1*<sup>-/+</sup> tumours were p-Erk1/2<sup>Thr202/Tyr204</sup>-positive but none of them were p-Akt<sup>Ser473</sup>-positive ([figure 1F](#)). These data suggest that—comparable to published data in breast and colon carcinomas<sup>18</sup>—the Mek/Erk axis is the *in vivo* driving force of *Kras*<sup>G12D</sup>-mediated mTOR activation in established tumours. Maintenance of mTOR signalling is also not dependent on PI3K/Akt in this mouse model, at least in the context of *Tsc1* level reduction. Therefore, the role of PI3K/Akt-mediated mTOR hyperactivation in pancreatic carcinogenesis cannot be directly addressed using such models.

To delineate the oncogenic *Kras*-independent function of *Tsc1* haploinsufficiency and to assess its hypothetical stand-alone tumour-suppressing potential, we followed up a cohort of *Ptf1a*<sup>Cre/+</sup>; *Tsc1*<sup>fl/+</sup> mice for 1.5 years (n=14, herein referred to as *Tsc1*<sup>-/+</sup>). These animals were healthy and no pancreas pathologies or hyperactivated mTOR signalling were observed (see online supplementary figure S2A, B). This suggests that *Tsc1* haploinsufficiency alone is largely tolerable in terms of pancreas function.

### ***Tsc1* (haplo)insufficiency facilitates the relay of PI3K/Akt signals to mTOR and promotes the development of cystic lesions in the pancreas**


Oncogenic *Kras* has been proposed to also induce pancreatic cancer through PI3K/Akt signalling. *Pten* is a negative regulator of PI3K and its deficiency has been reported to lead to initiation of PDAC in mice.<sup>4 19</sup> Since *Pten* was induced in *Tsc1*<sup>-/-</sup> pancreata (see online supplementary figure S2A), we reasoned that the feedback to mTOR was intact in these animals. We further hypothesised that *Tsc1* haploinsufficiency might facilitate the relay of PI3K/Akt signals to mTOR in the setting of concomitant

*Pten* deficiency. This would then be a possible alternative, oncogenic *Kras*-independent channel towards pancreatic carcinogenesis. To address these questions, *p48*<sup>Cre/+</sup>; *Pten*<sup>fl/fl</sup>; *Tsc1*<sup>fl/+</sup> mice (referred to as *Pten*<sup>-/-</sup>; *Tsc1*<sup>-/+</sup>) were generated. Although there was no significant difference in median survival between *Pten*<sup>-/-</sup>; *Tsc1*<sup>-/+</sup> and *Pten*<sup>-/-</sup> mice (132 days, n=18 vs 162 days, n=7; [figure 2A](#)), all *Pten*<sup>-/-</sup>; *Tsc1*<sup>-/+</sup> mice developed macroscopically visible pancreatic cysts ([figure 2B](#); *Pten*<sup>-/-</sup> mice: only focal cystic lesions, [figure 2C](#), as published<sup>19</sup>). A large proportion of the pancreatic parenchyma (40–100%) was replaced by large cysts, lined by flat-to-tall columnar epithelial cells, and/or smaller cysts with a cribriform architecture ([figure 2D](#), middle and right panel). There was intracystic and stromal inflammation ([figure 2D](#), left panel). Low-grade pancreatic intraepithelial neoplasias (PanIN1-2; see online supplementary figure S3A), but no PanIN3 were seen in the vicinity of the cystic lesions. In addition, we frequently observed acinar-to-ductal metaplasias, positive for Krt19, within the atrophic pancreatic parenchyma, similar to lesions previously described in *Pten*<sup>-/-</sup> mice<sup>20–22</sup> (see online supplementary figure S3B). These cystic lesions (6/6) were positive for p-Akt<sup>Ser473</sup>, p-mTOR<sup>Ser2448</sup> and p-S6<sup>Ser235/236</sup>, but negative for p-Erk1/2<sup>Thr202/Tyr204</sup> ([figure 2F](#); 5/6, except for one invasive case; online supplementary figure S3C), suggesting a PI3K/Akt-dependent activation of mTOR *in vivo*. Only one invasive PDAC was found (1/18; 6%, [figure 2E](#), left panel) in which small invasive carcinomas were surrounded by  $\alpha$ -smooth muscle actin-positive mesenchymal cells ([figure 2E](#), right panel). Thus, *Tsc1* haploinsufficiency together with a loss of *Pten* facilitate PI3K/Akt signalling to mTOR *in vivo*, albeit at a relatively low penetrance. We also conclude from these data that—comparable to its effect in other entities such as lung cancer<sup>7</sup>—*Tsc1* functions as a PDAC tumour suppressor by facilitating mTOR hyperactivation. Interestingly and depending on the upstream stimulating signals (Mek/Erk vs PI3K/Akt), *Tsc1* haploinsufficiency leads to different biological results (eg, metastatic PDAC vs cystic lesions).

### **Dual inhibition of Mek and PI3K effectively decreases oncogenic *Kras*/Mek/Erk-dependent mTOR activity**

To further define the interaction of mTOR and oncogenic *Kras* signalling, including reciprocal activation/inhibition of upstream and downstream signals, cell lines from *Kras*<sup>G12D/+</sup>; *Tsc1*<sup>-/+</sup> tumours (#399, 403, 907 and 897) and from *Pten*<sup>-/-</sup>; *Tsc1*<sup>-/+</sup> cystic lesions (#952, 926 and 928; see online supplementary figure S4A) were generated. The genotypes of the cell lines were confirmed by PCR (see online supplementary figure S4B). To ensure that the isolation process had not changed the cells overtly, they were orthotopically transplanted into C57Bl/6 (*Kras*<sup>G12D/+</sup>; *Tsc1*<sup>-/+</sup> cell lines) or subcutaneously into BALB/c nude (*Pten*<sup>-/-</sup>; *Tsc1*<sup>-/+</sup> cell lines) mice. No tumour formation was observed during the transplantation of *Pten*<sup>-/-</sup>; *Tsc1*<sup>-/+</sup> cell lines into C57Bl/6 mice (see online supplementary table S1). The major morphologies of the primary tumours in *Kras*<sup>G12D/+</sup>; *Tsc1*<sup>-/+</sup> mice, including necrosis and dedifferentiation, were recapitulated in the orthotopic tumours (see online supplementary figure S4C and table S1). Similarly, subcutaneous injection of *Pten*<sup>-/-</sup>; *Tsc1*<sup>-/+</sup> cell lines induced cystic tumours, reminiscent of the respective primary lesions (see online supplementary figure S4D and table S1). We, therefore, decided that it was reasonable to use these cell lines in the following signal transduction experiments.

First, we tested the driving signal of mTOR in the respective cell lines by culturing the cells under serum deprivation conditions. In accordance with the *in vivo* findings, Akt was constitutively active (as demonstrated by p-Akt<sup>Ser473</sup> stainings) in *Pten*<sup>-/-</sup>; *Tsc1*<sup>-/+</sup> cells, whereas its activity in *Kras*<sup>G12D/+</sup>; *Tsc1*<sup>-/+</sup>




**Figure 1** Tsc1 (haplo)insufficiency facilitates oncogenic Kras/Mek/Erk signalling to mTOR, promoting development of metastatic PDACs. (A) Kaplan-Meier survival analysis shows *Kras*<sup>G12D/+</sup>; *Tsc1*<sup>-/+</sup> mice survival time (median survival 328 days; n=22) to be significantly shorter than *Kras*<sup>G12D/+</sup> mice (median survival 412 days; n=34), log-rank test: p<0.05; (B) tumour incidence and metastatic rate of *Kras*<sup>G12D/+</sup>; *Tsc1*<sup>-/+</sup> mice are higher than *Kras*<sup>G12D/+</sup> mice; tumour incidence ( $\chi^2$  test, p<0.05); metastasis rate ( $\chi^2$  test, p<0.01); (C) gross pathology of a *Kras*<sup>G12D/+</sup>; *Tsc1*<sup>-/+</sup> mouse pancreatic tumour shows the primary tumour (Pa), hepatic metastasis (Li) and pulmonary metastasis (Lu); (D) representative H&E-stained sections of *Kras*<sup>G12D/+</sup>; *Tsc1*<sup>-/+</sup> pancreata show invasive PDAC with sarcomatoid/dedifferentiation features (left panel, arrow: sarcomatoid-like area; scale bar: 50  $\mu$ m) and large areas of necrosis (right panel, \* necrosis; scale bar: 200  $\mu$ m); (E) representative H&E-stained sections display hepatic metastasis (left panel; scale bar: 100  $\mu$ m), pulmonary metastasis (middle panel; scale bar: 200  $\mu$ m) and renal invasion (right panel; scale bar: 100  $\mu$ m) in *Kras*<sup>G12D/+</sup>; *Tsc1*<sup>-/+</sup> mice; (F) representative IHC pictures show distinct in vivo activation of Akt (p-Akt<sup>Ser473</sup>), Erk (p-Erk1/2<sup>Thr202/Tyr204</sup>) and mTOR signalling (p-mTOR<sup>Ser2448</sup> and p-S6<sup>Ser235/236</sup>) in pancreatic tissues from *Kras*<sup>G12D/+</sup>; *Tsc1*<sup>-/+</sup> mice, scale bar: 50  $\mu$ m. Tsc, tuberous sclerosis complex; mTOR, mammalian target of rapamycin; PDAC, pancreatic ductal adenocarcinoma; Li, liver; Lu, lung; K, Kidney.

cell lines relied on the presence of serum in the culture medium. Accordingly, Erk was constantly active (p-Erk1/2<sup>Thr202/Tyr204</sup>) in *Kras*<sup>G12D/+</sup>; *Tsc1*<sup>-/+</sup> cell lines, while its activity in *Pten*<sup>-/-</sup>; *Tsc1*<sup>-/+</sup> cells also depended on serum concentration (figure 3A). Nevertheless, mTOR signalling (as reflected by phosphorylation levels of p-mTOR<sup>Ser2448</sup> and p-mTOR<sup>Ser2481</sup>) was constantly active in these cell lines and in some cases could be further increased by serum treatment (eg, the 403 and 907 cells). To distinguish patterns of mTOR activation, we analysed phosphorylation of the conserved Akt site of Tsc2 in *Pten*<sup>-/-</sup>; *Tsc1*<sup>-/+</sup> cells. Tsc2<sup>Ser939</sup> was significantly more phosphorylated than in *Kras*<sup>G12D/+</sup>; *Tsc1*<sup>-/+</sup> cells (figure 3A). As the levels of the Erk phosphorylation site of Tsc2 (Tsc2<sup>Ser664</sup>) could not be shown directly (due to the lack of effective antibodies), we proceeded to detect the Ampk phosphorylation site of Tsc2 as an internal control. No such difference was seen for the Ampk phosphorylation site of Tsc2 (Ser<sup>1837</sup>; figure 3A). Thus, mTOR activation in *Pten*<sup>-/-</sup>; *Tsc1*<sup>-/+</sup> cells is driven to a greater extent by the PI3K/Akt axis, whereas in *Kras*<sup>G12D/+</sup>; *Tsc1*<sup>-/+</sup> cells, Mek/Erk is more likely to be the driving force.

In order to further substantiate such activation patterns, we investigated the influence of pharmacological inhibition of Mek (using the MEK inhibitor PD 98059), PI3K (using the PI3K

inhibitor LY 294002) and/or mTOR (using rapamycin) signalling in *Kras*<sup>G12D/+</sup>; *Tsc1*<sup>-/+</sup> ('399 cells') and *Pten*<sup>-/-</sup>; *Tsc1*<sup>-/+</sup> ('926 cells') cells, respectively. In *Kras*<sup>G12D/+</sup>; *Tsc1*<sup>-/+</sup> cells (figure 3B, left panel), inhibition of Mek alone had no effect on mTOR activity. This was mainly due to the feedback activation of Akt which reactivated mTOR by phosphorylating Tsc2. Similarly, inhibition of PI3K alone had no significant effect. Direct inhibition of mTOR elicited strong feedback activation of Erk which counteracted mTOR inhibition; furthermore, the *Kras*<sup>G12D/+</sup>; *Tsc1*<sup>-/+</sup> cells were highly resistant to the cytotoxic effect of rapamycin (as compared with *Pten*<sup>-/-</sup>; *Tsc1*<sup>-/+</sup> cells, figure 3C). Only dual inhibition of Mek and PI3K reduced mTOR activity. Even more importantly, only this combinatorial inhibition effectively induced apoptosis (figure 3D (fluorescence-activated cell sorting (FACS)) and online supplementary figure S4E (cleaved caspase 3)). In *Pten*<sup>-/-</sup>; *Tsc1*<sup>-/+</sup> cells, however, inhibition of Mek had no effect whereas inhibition of PI3K reduced mTOR activity. Dual inhibition of Mek and PI3K or direction inhibition of mTOR had similar effects (see online supplementary figure 3B, right panel).

Thus, while cells derived from *Kras*<sup>G12D/+</sup>; *Tsc1*<sup>-/+</sup> tumours are resistant to Mek, PI3K and mTOR inhibitors alone, the dual inhibition of the Mek/Erk and PI3K/Akt cascades effectively



**Figure 2** *Tsc1* (haplo)insufficiency facilitates the relay of PI3K/Akt signals to mTOR and promotes the development of cystic lesions in the pancreas. (A) Kaplan-Meier survival analysis shows *Pten*<sup>-/-</sup>; *Tsc1*<sup>+/-</sup> mice survival times (median survival 132 days; n=18) not to be significantly different than *Pten*<sup>-/-</sup> mice (median survival 162 days; n=7), log-rank test: p>0.05; (B) gross pathology of *Pten*<sup>-/-</sup>; *Tsc1*<sup>+/-</sup> mice shows pancreatic cysts at necropsy; (C) representative H&E-stained sections indicate localised cystic lesions in *Pten*<sup>-/-</sup> pancreata; scale bar: 500  $\mu$ m (left), 50  $\mu$ m (right); (D) representative H&E-stained sections of *Pten*<sup>-/-</sup>; *Tsc1*<sup>+/-</sup> pancreata indicate exocrine pancreas remodelling by cystic lesions with high-grade dysplasia in smaller cysts with cribriform architecture (\* intracystic and stromal inflammatory component, scale bar: 500  $\mu$ m (left), 200  $\mu$ m (middle), 100  $\mu$ m (right)); (E) H&E-stained section demonstrates one case of focal invasion in *Pten*<sup>-/-</sup>; *Tsc1*<sup>+/-</sup>; the invasive cells are surrounded by  $\alpha$ -SMA-positive mesenchymal cells (scale bar: 50  $\mu$ m); (F) representative IHC pictures show distinct in vivo activation of Akt (p-Akt<sup>Ser473</sup>), Erk (p-Erk1/2<sup>Thr202/Tyr204</sup>) and mTOR signalling (p-mTOR<sup>Ser2448</sup> and p-S6<sup>Ser235/236</sup>) in pancreatic tissues of *Pten*<sup>-/-</sup>; *Tsc1*<sup>+/-</sup> mice, scale bar: 50  $\mu$ m. Tsc, tuberous sclerosis complex; mTOR, mammalian target of rapamycin;  $\alpha$ -SMA,  $\alpha$ -smooth muscle actin.

inhibited mTOR activation and induced apoptosis. Such a dual inhibition would be a reasonable clinical approach for the treatment of patients with PDACs with oncogenic *Kras* mutation(s) and concomitant Mek/Erk-mediated mTOR activation. The aim of the following analyses was to identify biomarkers for this presumed subset of patients.


#### **Aldh1a3 is a biomarker for oncogenic *Kras*/Mek/Erk/mTOR-driven PDAC**

We compared transcriptional profiles of a panel of *Kras*<sup>G12D/+</sup>; *Tsc1*<sup>+/-</sup> cell lines to *Pten*<sup>-/-</sup>; *Tsc1*<sup>+/-</sup> cells. As no cell lines could be retrieved from the *Tsc1*<sup>+/-</sup> mice, we established cell lines from pancreata of *p48*<sup>Crel/+</sup>; *p53*<sup>fl/fl</sup>; *Tsc1*<sup>fl/+</sup> and *p48*<sup>Crel/+</sup>; *p53*<sup>fl/fl</sup>; *Tsc1*<sup>fl/fl</sup> (described as *p53*<sup>fl/fl</sup>; *Tsc1*<sup>fl/+</sup> and the *p53*<sup>fl/fl</sup>; *Tsc1*<sup>fl/fl</sup>, respectively) mice as controls (see online supplementary figure S5A). No PDAC formation was observed in any of these animals. The purpose of the *Pten*<sup>-/-</sup>; *Tsc1*<sup>+/-</sup>; *p53*<sup>fl/fl</sup>; *Tsc1*<sup>fl/+</sup> and *p53*<sup>fl/fl</sup>; *Tsc1*<sup>fl/fl</sup> cell lines was to filter out target and other 'background' genes of the PI3K/Akt-mTOR axis.

Using 0.001 as the statistical cut-off for the false discovery rate, 4234 genes were found to be differentially expressed between any pair of cell lines (which represent 20.4% of all genes on the array; the top 100 genes are listed in online supplementary table S2). The 20 genes specifically upregulated in *Kras*<sup>G12D/+</sup>; *Tsc1*<sup>+/-</sup> cell lines were named '*Kras*<sup>G12D</sup>/Mek-mTOR signature', while the 20 genes upregulated in the *Pten*<sup>-/-</sup>; *Tsc1*<sup>+/-</sup> cell lines were labelled '*PI3K/Akt-mTOR*

signature' (figure 4A). Out of these, *Cdh17* (liver-intestine cadherin), *Wfdc2* (also known as HE4, WAP four-disulfide core domain 2) and *Gabrp* ( $\gamma$ -aminobutyric acid A receptor, pi) were shared by the *Kras*<sup>G12D</sup>/Mek-mTOR and PI3K/Akt-mTOR signatures (figure 4A, C). These genes have previously been reported to be expressed in human PDAC tissues and cell lines, indicating that the mouse cell lines at least partially represent human disease genetics.<sup>23-26</sup>

We then focused on the *Kras*<sup>G12D</sup>/Mek-mTOR signature. The genes for the Mek/Erk-mTOR signature were selected if they were significantly upregulated in *Kras*<sup>G12D/+</sup>; *Tsc1*<sup>+/-</sup> cell lines compared with both *Pten*<sup>-/-</sup>; *Tsc1*<sup>+/-</sup> and control cell lines (two independent t tests, p<0.05, FC>2), yielding a gene set containing 230 genes (see online supplementary table S3). To explore the functional relevance of this signature, we analysed Gene Ontology (GO) terms and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways using the 230 preselected genes. This analysis revealed that 87 GO terms (see online supplementary table S4) were over-represented in the Mek/Erk-mTOR signature; the top GO terms are listed in online supplementary table S5. The majority of GO terms were associated with cell proliferation, cell differentiation, metabolic processes, cellular response to stress, regulation of MAP kinases and other kinase activities, which is largely in line with the known functions of Mek/Erk-mTOR signalling. Notably, KEGG pathway analysis identified 'Glycolysis/Gluconeogenesis' as a significant pathway (see online supplementary tables S4 and S5). These data




**Figure 3** Dual inhibition of Mek and PI3K effectively decreases oncogenic Kras/Mek/Erk-dependent mTOR activity. (A) Western-blot analysis demonstrates phosphorylation levels of p-Akt<sup>Ser473</sup>, p-Erk1/2<sup>Thr202/Tyr204</sup>, p-mTOR<sup>Ser2448</sup>, p-mTOR<sup>Ser2481</sup>, p-Tsc2<sup>Ser939</sup> and p-Tsc2<sup>Ser1387</sup> in *Pten*<sup>-/-</sup>; *Tsc1*<sup>-/-</sup> (926, 928 and 952) and *Kras*<sup>G12D/+</sup>; *Tsc1*<sup>-/-</sup> (399, 403, 907 and 897) cells after FBS treatment for 2 h; one of the three independent experiments is shown; (B) western-blot analysis shows phosphorylation levels of p-Erk1/2<sup>Thr202/Tyr204</sup>, p-Akt<sup>Ser473</sup>, p-mTOR<sup>Ser2448</sup>, p-Tsc2<sup>Ser939</sup> after pharmacological inhibition of MEK (PD 98069), PI3K (LY 294002), MEK+PI3K and mTOR (rapamycin) for 24 h in *Kras*<sup>G12D/+</sup>; *Tsc1*<sup>-/-</sup> and *Pten*<sup>-/-</sup>; *Tsc1*<sup>-/-</sup> cells, respectively; (C) in vitro chemotherapy assay indicates that *Kras*<sup>G12D/+</sup>; *Tsc1*<sup>-/-</sup> cells are more resistant to rapamycin than *Pten*<sup>-/-</sup>; *Tsc1*<sup>-/-</sup> cells; \* p<0.05. (D) FACS analysis for Annexin V demonstrates apoptosis in *Kras*<sup>G12D/+</sup>; *Tsc1*<sup>-/-</sup> cells following dual inhibition of MEK and PI3K. One representative experiment of three is shown. Tsc, tuberous sclerosis complex; FBS, fetal bovine serum; mTOR, mammalian target of rapamycin; MEK-I, MEK inhibition; PI3K-I, PI3K inhibition; mTOR-I, mTOR inhibition.

underscore the importance of Mek/Erk-mTOR signalling for regulating glucose metabolism in pancreatic carcinogenesis, as recently described.<sup>27</sup> The gene with the lowest p value was *Aldh1a3* (aldehyde dehydrogenase 1 family, member A3). Though ALDH1 expression is an unfavourable factor for patient prognosis,<sup>28 29</sup> it is unclear which ALDH1 contributes to the aggressive biology of ALDH1-expressing cancers. We, therefore, analysed expression of 20 Aldh family members in the cell lines, revealing that Aldh1a3 was associated with the *Kras*<sup>G12D</sup>/Mek-mTOR signature while Aldh1a1 was associated with the PI3K/Akt-mTOR signature (figure 4B, D). In vivo validation of these molecular signatures was carried out using immunohistochemistry studies for Aldh1a3, Aldh1a1 and two further proteins—Tensin 4 (Tns4) and Amphiregulin (Areg), which were among the top 20 genes of the Mek/Erk-mTOR signature (figure 4E). In line with the array data, cancer cells in *Kras*<sup>G12D/+</sup>; *Tsc1*<sup>-/-</sup> mice were positive for Aldh1a3, Tns4 and Areg, and negative for Aldh1a1. In contrast, cystic lesions in *Pten*<sup>-/-</sup>; *Tsc1*<sup>-/-</sup> mice were positive for Aldh1a1, but negative for Aldh1a3, Tns4 and Areg (figure 4E). Importantly, one *Pten*<sup>-/-</sup>; *Tsc1*<sup>-/-</sup> pancreas with an invasive cyst showed high levels of Aldh1a3, implying that Aldh1a3 expression is associated with malignant transformation (see online supplementary figure S3C).

### Aldh1a3 promotes the growth of oncogenic Kras-dependent and Kras-independent cell lines

Because our bioinformatic analysis of the Mek/Erk-mTOR signature identified glucose metabolism as a crucial process for its oncogenic activity and because Aldh1a3 has recently been shown to promote glycolysis in glioma stem cells,<sup>30</sup> we hypothesised that the oncogenic activity of the Mek/Erk-mTOR axis may rely on Aldh1a3. To analyse this, we confirmed Aldh1a3 and Aldh1a1 expression (as a 'control') in *Kras*<sup>G12D/+</sup>; *Tsc1*<sup>-/-</sup> and *Pten*<sup>-/-</sup>; *Tsc1*<sup>-/-</sup> cell lines, respectively (figure 5A). To substantiate whether the *Kras*<sup>G12D</sup>/Mek-mTOR axis controls Aldh1a3 expression, we investigated the influence of pharmacological inhibition of Mek, PI3K and/or mTOR signalling on Aldh1a3 and Aldh1a1 expression in *Kras*<sup>G12D/+</sup>; *Tsc1*<sup>-/-</sup> (399 cells) and *Pten*<sup>-/-</sup>; *Tsc1*<sup>-/-</sup> (926 cells) cells, respectively. In accordance with results from our pathway analyses (figure 3B), dual inhibition of Mek and PI3K reduced both the activity of the *Kras*<sup>G12D</sup>/Mek-mTOR axis and Aldh1a3 expression in *Kras*<sup>G12D/+</sup>; *Tsc1*<sup>-/-</sup> cells. Inhibition of Mek, PI3K and mTOR alone had no such effect, despite the finding that single inhibition of Mek or PI3K slightly decreased Aldh1a3 expression in these cells (figure 5B). In *Pten*<sup>-/-</sup>; *Tsc1*<sup>-/-</sup> cells, inhibition of PI3K and mTOR or dual inhibition of PI3K and Mek eliminated




**Figure 4** Aldh1a3 is a biomarker for oncogenic Kras/Mek/Erk/mammalian target of rapamycin (mTOR)-driven pancreatic ductal adenocarcinoma. (A) A heatmap illustrates the 20-gene signature representing different groups of cell lines and (B) expression of 20 Aldh members in the three groups of cell lines. The bar graph shows the relative expression of Cdh17, Wfdc2, Gabrp (C) as well as of Aldh1a1 and Aldh1a3 (D) in different groups of cell lines; (E) IHC demonstrates expression of Aldh1a3, Aldh1a1, Areg and Tns4 in cystic lesions and cancer cells of *Pten*<sup>-/-</sup>; *Tsc1*<sup>-/+</sup> and *Kras*<sup>G12D/+</sup>; *Tsc1*<sup>-/+</sup> mice, respectively; scale bar: 50 μm.

both mTOR activity and Aldh1a1 expression (see online supplementary figure S5B). Interestingly, *Kras*<sup>G12D/+</sup>; *p53*<sup>R172H/+</sup> cancer cell lines ('5M407' and '110365' cells, obtained from *Pdx1-Cre*; *Kras*<sup>G12D/+</sup>; *p53*<sup>R172H/+</sup> mice, respectively) expressed significantly lower levels of Aldh1a3 as compared with *Kras*<sup>G12D/+</sup>; *Tsc1*<sup>-/+</sup> cells (see online supplementary figure 6SA). Dual inhibition of Mek/PI3K in these cells eliminated mTOR activity but had no effect on Aldh1a3 expression (see online supplementary figure S6B).

To analyse the functional relevance of Aldh1a3, we reduced Aldh1a3 expression in *Kras*<sup>G12D/+</sup>; *Tsc1*<sup>-/+</sup> cells ("399 cells")

using Aldh1a3-specific sh-RNA expression vectors (figure 5C, upper panel). In line with the bioinformatics analysis and previously reported data,<sup>30</sup> we observed a significant reduction in the concentration of lactic acid in the supernatants following Aldh1a3 sh-RNA (see online supplementary figure S6C; cells cultured in normal medium, glucose 25 mM), suggesting impaired glycolysis. No such effect was observed when these cells were cultured in a low-glucose (0.5 mM) medium. Notably, downregulation of Aldh1a3 significantly impaired the growth of *Kras*<sup>G12D/+</sup>; *Tsc1*<sup>-/+</sup> cells after they had been transplanted into WT mice (figure 5A, lower panel). To substantiate these findings



**Figure 5** Aldh1a3 promotes the growth of oncogenic Kras-dependent and Kras-independent cell lines. (A) Western-blot analysis shows expression of Aldh1a3 and Aldh1a1 in the three groups of cell lines; (B) western-blot analysis shows Aldh1a3 expression after pharmacological inhibitions of MEK (PD 98069), PI3K (LY 294002), MEK+PI3K and mTOR (rapamycin) for 24 h in *Kras*<sup>G12D/+</sup>; *Tsc1*<sup>-/-</sup> cells, respectively; one experiment out of three is shown; (C) western-blot analysis shows selected clones (*Kras*<sup>G12D/+</sup>; *Tsc1*<sup>-/-</sup> cells, 399) stably expressing Aldh1a3-specific shRNA (upper panel); the tumour mass of orthotopically transplanted cancer cells (control#1, Aldh1a3-shRNA#1 and Aldh1a3-shRNA#3) in WT mice (lower panel); \* $<0.05$ ; (D) western-blot analysis shows selected clones (*Pten*<sup>-/-</sup>; *Tsc1*<sup>-/-</sup> cells, 926) stably expressing Aldh1a3 (upper panel); the tumour size shows growth of transplanted cancer cells (EV#1 and EV#2, Aldh1a3#1, Aldh1a3#2 and Aldh1a3#4) in BALB/c nude mice (lower panel); \* $<0.05$ . Tsc, tuberous sclerosis complex; mTOR, mammalian target of rapamycin; MEK-I, MEK inhibition; PI3K-I, PI3K inhibition; mTOR-I, mTOR inhibition; control, control vector; WT, wild type; EV, empty vector


in a non-Kras-dependent model, we generated stable Aldh1a3-expressing *Pten*<sup>-/-</sup>; *Tsc1*<sup>-/-</sup> cell lines (termed “#926”, figure 5B, upper panel). These produced significantly larger tumours after subcutaneous transplantation into BALB/c nude mice (figure 5B, lower panel). However, overexpression of Aldh1a3 itself did not impact the activities of Erk, Akt or mTOR (see online supplementary figure S6D). In contrast, transient downregulation of Aldh1a3 using siRNA transfection slightly compromised cell growth of one of the *Kras*<sup>G12D/+</sup>; *p53*<sup>R172H/+</sup> cell lines (“110365” cells; 23% reduction, colony formation assay; online supplementary figure S6E).

#### ALDH1A3 labels an aggressive subtype of human PDAC

Since Aldh1a3 is a biomarker of aggressiveness in mouse *Kras*<sup>G12D/+</sup>; *Tsc1*<sup>-/-</sup> PDACs and because it promotes tumour growth in vivo, we attempted to determine if this was the case in humans as well. ALDH1A3 mRNA was significantly upregulated in bulk PDAC (n=20) tissues (fivefold, compared with normal pancreas (n=10)), while ALDH1A1 mRNA was downregulated (figure 6A). Subsets of human PDAC cell lines expressed ALDH1A3 and/or ALDH1A1, respectively (figure 6B). In line with the results from the mouse cell lines, only dual inhibition

of MEK/PI3K effectively eliminated mTOR activity and ALDH1A3 expression in human pancreatic cancer cell lines (Su86.86 and BxPC-3 cells, online supplementary figure S7A). Twenty-four-hour inhibition of PI3K or mTOR alone reduced mTOR activity in these cells; however, it elicited a feedback to AKT signalling, as also previously described.<sup>11 28</sup> At the same time, it had no effect on ALDH1A3 expression. Dual inhibition of mTORC1/2, of PI3K/mTOR, or direct inhibition of AKT circumvented the feedback to AKT signalling; however, none of these inhibitions had any effect on ALDH1A3 expression (see online supplementary figure S7B). These data demonstrate that the PI3K/AKT-mTOR axis does not contribute to ALDH1A3 expression. 41% (21/50) of PDAC tissues reacted ALDH1A3-positive during immunohistochemistry (figure 6C). Kaplan-Meier survival analysis revealed that patients with cancer tissues positive for ALDH1A3 survived for a significantly shorter time after surgical resection than those testing negative for ALDH1A3 (median survival: 14.0 vs 22.8 months, figure 6C). The prognostic value of ALDH1A3 expression was validated by multivariable analysis using a Cox proportional hazards model (see online supplementary table S6, HR 2.374, p=0.040). Further analysis demonstrated that ALDH1A3





**Figure 6** ALDH1A3 labels an aggressive subtype of human pancreatic ductal adenocarcinoma (PDAC). (A) QRT-PCR data demonstrate mRNA levels of ALDH1A1 and ALDH1A3 in normal pancreas (n=10) and PDAC tissues (n=20); data are presented as relative expression (normalised to the median expression level in normal pancreas); \*p<0.05; (B) western-blot analysis show protein expression of ALDH1A1 and ALDH1A3 in human PDAC cell lines (Aspc-1 (As), Capan-1 (Ca), Colo357 (Co), Panc-1 (Pa), Bx (Bxpc-3), Mia-PaCa2 (Mi), T3M4 (T3), Su86.86 (Su)); data are presented as relative expression (normalised to the median expression level of all cell lines); (C, D) IHC pictures show ALDH1A3-expressing and ALDH1A1-expressing PDAC cells; patients with PDAC whose cancer tissues are positively stained for ALDH1A3 (n=21) survived significantly shorter than those with ALDH1A3 negativity (n=29; median survival: 14.0 vs 22.8 months, log-rank test: p=0.012); however, there is no such effect for ALDH1A1; (E) representative H&E-stained sections and immunohistochemistries show the histology and expression of ALDH1A3, ALDH1A1, AREG and TNS4 in 14 human xenograft PDACs.

expression was associated with the lymph node (N) status of the patients on univariable analysis. Ninety-five per cent (20/21) of patients with ALDH1A3-positive tumours had cancer-positive lymph nodes at time of surgery (table 1). Though 47% (22/46) of the human PDAC tissues were strongly positive for ALDH1A1, their staining intensities did not correlate with survival (figure 6D). We stained 14 human PDAC xenograft tissues (tumours derived from primary human PDACs) for ALDH1A3, ALDH1A1, TNS4 and AREG to further validate if ALDH1A3-positive PDACs constitute a molecular subtype in humans and to potentially screen therapeutic options for this subtype. This analysis revealed that positivity of TNS4 and AREG strictly correlated with the expression of ALDH1A3 (figure 6E). Specifically, 6 of 14 (43%) PDAC tissues were positive for ALDH1A3 while 5 (5/6; 83.3%) were double-positive for TNS4 and AREG. In contrast, only 1 of 8 (12.5%) ALDH1A3-negative tissues was double-positive for TNS4 and

AREG. However, 93% of the tissues (13/14) were positive for ALDH1A1 and here, no correlation to TNS4 and AREG expression was found.

## DISCUSSION

Using a set of transgenic mouse models, we performed an extensive in vivo molecular/phenotypic dissection on the physiological role of mTOR signalling in pancreas. In the context of Tsc1 haploinsufficiency, *Kras*<sup>G12D</sup> preferably activated mTOR via the Mek/Erk cascade. This was sufficient and effective enough to initiate PDAC at a 95% penetrance. These data define the Mek/Erk cascade as the backbone of mTOR activation in *Kras*<sup>G12D</sup>-driven PDAC. Owing to reciprocal activation and inhibition between mTOR, and its driving and downstream signals, inhibition of none of the tested signal relays within the *Kras*<sup>G12D</sup>/Mek-mTOR axis was sufficient to reduce its activity or to increase cancer cell apoptosis. Expression analysis of the

**Table 1** Clinical characteristics and comparisons of the two pancreatic ductal adenocarcinoma cohorts

	ALDH1A3 negative	ALDH1A3 positive	p Value	Total
Age (years, median)	67.0	66.0	0.73*	–
Gender				
Male	12	13	0.15†	25
Female	17	8	0.25‡	25
Size of tumour (T)				
T2	3	2	0.39†	5
T3	21	18	0.41‡	39
T4	5	1		6
Lymph node (N)				
N0	12	1	0.004†	13
N1	17	20	0.002‡	37
Metastasis (M)				
M0	27	20	0.75†	47
M1	2	1	1.0‡	3
Grade (G)				
G1	5	0	0.11†	5
G2	10	7	0.11‡	17
G3	14	14		28
Resection status				
R0	13	13	0.12†	26
R1	11	8	0.12‡	19
Unknown	5	0		5
Chemotherapy				
Yes	25	15	0.29†	40
No	4	6		10

\*Mann-Whitney U test.

† $\chi^2$  Test.

‡Fisher's exact test.

respective cell lines identified Aldh1a3 as a key target gene of *Kras*<sup>G12D</sup>/Mek-mTOR, both on the expression and the function levels. Our data clearly define the *Kras*<sup>G12D</sup>/Mek/mTOR/Aldh1a3 axis as a major therapeutic target in a particular subset of Aldh1a3-positive PDAC.

Two recent transposon mutagenesis projects have identified and confirmed Pten as an important tumour suppressor in oncogenic *Kras*-driven cancers.<sup>31–32</sup> A preclinical trial in transgenic mouse models discovered that *Kras*<sup>G12D</sup> mice with Pten deficiency were particularly sensitive to mTOR inhibition, whereas *Kras*<sup>G12D</sup> mice with mutant p53 were highly resistant.<sup>13</sup> A new concept of mTOR dependency in PDAC has been proposed based on these data. It highlights a role of PI3K/Akt-driven mTOR signalling in promoting oncogenic *Kras*-driven carcinogenesis. The resulting tumours are, however, more susceptible to mTOR inhibition.<sup>13</sup> Though only a subset of human PDACs (20–30%) includes genetic changes along the PI3K/AKT pathway,<sup>3–31</sup> mTOR hyperactivation is found at much higher rates of approximately 80%. This indicates an alternative activation of mTOR by oncogenic *Kras* in the absence of genetic changes along the PI3K/AKT axis. In addition, these tumours would probably respond less to mTOR inhibition—as shown in the frustrating results of clinical trials published to date.<sup>10</sup>

In this paper, we describe a novel mouse model in which mTOR signalling is activated in the absence of active PI3K/Akt signalling by deleting one allele of *Tsc1* and by concomitantly expressing oncogenic *Kras*. We speculate that one *Tsc1* allele may affect the stability of the Tsc, which leads to a reduced activation threshold of mTOR by upstream signals such as Mek/Erk

and PI3K/Akt. Notably, we observed that cancer cell lines derived from these mice expressed relatively low levels of Aldh1a3 and that dual inhibition of Mek/PI3K reduced mTOR activity. This, however, had no effect on Aldh1a3 expression, which might be due to insufficient inhibition of mTOR activity under our experimental conditions or to alternative mechanisms of control of Aldh1a3 expression (eg, through a p53 gain-of-function mutation<sup>33</sup>).

In humans, the ALDH subfamily of NAD(P)<sup>+</sup>-dependent enzymes contains 19 isoforms which are mainly responsible for aldehyde detoxification and retinoid acid signalling (<http://www.aldh.org/>).<sup>34</sup> In particular, the ALDH1 family has been linked to characteristics of stem cells and cancer stem cells in various organs, including the pancreas.<sup>35</sup> Aldh1a1 and Aldh1a7 were reported to be expressed in pancreatic progenitor cells in the adult mouse pancreas.<sup>36</sup> Aldh1a1 and Aldh1b1 are expressed in pancreatic stem/progenitors cells in embryonic development.<sup>37</sup> Aldh1a2 is expressed in the dorsal pancreatic mesenchyme during pancreatic organogenesis and plays a role in guiding development of the dorsal pancreas.<sup>38</sup> However, expression of Aldh1a3 has not so far been reported under physiological circumstances in any type of pancreatic cells. Our data demonstrate that Aldh1a3 expression in pancreatic cancer cells promotes glycolysis and tumour formation in vivo which corresponds with the previously reported function of Aldh1a3 in glioma stem cells.<sup>30</sup> Furthermore, we demonstrate that it is the high expression of ALDH1A3 that correlates with poor prognosis in human PDAC, which is in line with the phenotype of the *Kras*<sup>G12D/+</sup>; *Tsc1*<sup>-/+</sup> mice. The data presented here also indicate that Aldh1a3 is not only a marker for these tumours but also constitutes an essential component of the *Kras*<sup>G12D</sup>/Mek-mTOR axis. Direct targeting of Aldh1a3 may, therefore, circumvent the feedback responses elicited by mTOR inhibition. However, there are two major questions worthwhile of further investigation: (1) How does the oncogenic *Kras*/Mek/Erk/mTOR axis control expression of Aldh1a3? and (2) How does Aldh1a3 affect glucose metabolism?

In conclusion, our results from mouse model and pathway analyses demonstrate the *Kras*<sup>G12D</sup>/Mek/mTOR/Aldh1a3 axis to be a therapeutic target in a PDAC patient subset. According to these data, about 40% of human PDAC tissues are positive for ALDH1A3. These patients might benefit from a dual inhibition of MEK and PI3K (or even ALDH1A3). Further research will be required to define the extent and timing of such a combinatorial treatment approach. Since the ALDH1A3-positive subtype also exists in human xenograft PDACs, the effectiveness of such therapies could be tested in a translational setting. The particular mouse models described here may serve as an additional testing platform.

#### Author affiliations

<sup>1</sup>Department of Surgery, Technische Universität München (TUM), Munich, Germany<sup>2</sup>Institute of Pathology, TUM, Munich, Germany<sup>3</sup>Institute of Computational Biology, Helmholtz-Zentrum München, Munich, Germany<sup>4</sup>Institute of Experimental Genetics (IEG), Helmholtz-Zentrum München, Munich, Germany<sup>5</sup>Technische Universität München, Chair of Experimental Genetics, Freising, Germany<sup>6</sup>Deutsches Zentrum für Diabetesforschung (DZD), Neuherberg, Germany<sup>7</sup>Department of Surgery, Koc University School of Medicine, Istanbul, Turkey<sup>8</sup>Department of Gastroenterology, TUM, Munich, Germany<sup>9</sup>Institute of Pathology, Ruhr-University Bochum, Bochum, Germany<sup>10</sup>Department of Molecular Gastrointestinal Oncology, Ruhr-University Bochum, Bochum, Germany<sup>11</sup>Department of Surgery, University of Heidelberg, Heidelberg, Germany

**Acknowledgements** The authors would like to thank Wilhelm Schönherr, Manja Thorwirth, Ziyang Jian, Nadja Maeritz, Nataliya Valkovska and Anke Bettenbrock for their excellent technical support.

**Contributors** BK, CWM and JK designed the study. BK, WW, TC, CQ, ZJ, IR, SR and NB performed experiments and acquired data. AMS and IE provided expertise in pathological analysis. CJ collected clinical data and provided expertise in statistical analysis. SAH and AT provided xenograft tissues and pathology diagnoses. PB, MI, JB and FJT provided expertise in bioinformatics. BK and CWM drafted the manuscript. ME, HF, JTS and JK revised the manuscript critically for important intellectual content. All authors approved the final version of the manuscript.

**Funding** This project was supported in part by a grant from the TU Munich commission for clinical research (KKF C21-11, to BK), the Deutsche Forschungsgemeinschaft (MI 1173/5-1, to CWM, BK and JK), the Else-Kroener-Fresenius-Stiftung (2009\_A146, to CWM), the European Union (FP7, PacaNet, to CWM and JK), the Deutsche Zentrum für Diabetesforschung—DZD e.V. (to JB) and the German Ministry of Science (North Rhine-Westphalia, Germany; PURE, to SAH).

**Competing interests** None.

**Ethics approval** Institutional Review Board, TU Munich, Germany.

**Provenance and peer review** Not commissioned; externally peer reviewed.

## REFERENCES

- Singh A, Greninger P, Rhodes D, *et al.* A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival. *Cancer Cell* 2009;15:489–500.
- Russo M, Di Nicolantonio F, Bardelli A. Climbing RAS, the everest of oncogenes. *Cancer Discov* 2014;4:19–21.
- Ying H, Elpek KG, Vinjamoori A, *et al.* PTEN is a major tumor suppressor in pancreatic ductal adenocarcinoma and regulates an NF-kappaB-cytokine network. *Cancer Discov* 2011;1:158–69.
- Eser S, Reiff N, Messer M, *et al.* Selective requirement of PI3K/PDK1 signaling for Kras oncogene-driven pancreatic cell plasticity and cancer. *Cancer Cell* 2013;23:406–20.
- Ardito CM, Gruner BM, Takeuchi KK, *et al.* EGF receptor is required for KRAS-induced pancreatic tumorigenesis. *Cancer Cell* 2012;22:304–17.
- Navas C, Hernandez-Porras I, Schuhmacher AJ, *et al.* EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma. *Cancer Cell* 2012;22:318–30.
- Liang MC, Ma J, Chen L, *et al.* TSC1 loss synergizes with KRAS activation in lung cancer development in the mouse and confers rapamycin sensitivity. *Oncogene* 2010;29:1588–97.
- Guo Y, Chekaluk Y, Zhang J, *et al.* TSC1 involvement in bladder cancer: diverse effects and therapeutic implications. *J Pathol* 2013;230:17–27.
- Kennedy AL, Morton JP, Manoharan I, *et al.* Activation of the PIK3CA/AKT pathway suppresses senescence induced by an activated RAS oncogene to promote tumorigenesis. *Mol Cell* 2011;42:36–49.
- Javle MM, Shroff RT, Xiong H, *et al.* Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies. *BMC Cancer* 2010;10:368.
- Soares HP, Ni Y, Kisfalvi K, *et al.* Different patterns of Akt and ERK feedback activation in response to rapamycin, active-site mTOR inhibitors and metformin in pancreatic cancer cells. *PLoS ONE* 2013;8:e57289.
- Wolpin BM, Hezel AF, Abrams T, *et al.* Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. *J Clin Oncol* 2009;27:193–8.
- Morran DC, Wu J, Jamieson NB, *et al.* Targeting mTOR dependency in pancreatic cancer. *Gut* 2014;63:1481–9.
- Hahn SA, Seymour AB, Hoque AT, *et al.* Allelotype of pancreatic adenocarcinoma using xenograft enrichment. *Cancer Res* 1995;55:4670–5.
- Munding JB, Adai AT, Maghnoouj A, *et al.* Global microRNA expression profiling of microdissected tissues identifies miR-135b as a novel biomarker for pancreatic ductal adenocarcinoma. *Int J Cancer* 2012;131:E86–95.
- Jones S, Zhang X, Parsons DW, *et al.* Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. *Science* 2008;321:1801–6.
- Hingorani SR, Petricoin EF, Maitra A, *et al.* Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. *Cancer Cell* 2003;4:437–50.
- Ma L, Teruya-Feldstein J, Bonner P, *et al.* Identification of S664 TSC2 phosphorylation as a marker for extracellular signal-regulated kinase mediated mTOR activation in tuberous sclerosis and human cancer. *Cancer Res* 2007;67:7106–12.
- Stanger BZ, Stiles B, Lauwers GY, *et al.* Pten constrains centroacinar cell expansion and malignant transformation in the pancreas. *Cancer Cell* 2005;8:185–95.
- Al-Ghamdi S, Albasri A, Cachat J, *et al.* Cten is targeted by Kras signalling to regulate cell motility in the colon and pancreas. *PLoS ONE* 2011;6:e20919.
- Al-Ghamdi S, Cachat J, Albasri A, *et al.* C-Terminal Tensin-like gene functions as an oncogene and promotes cell motility in pancreatic cancer. *Pancreas* 2013;42:135–40.
- Ling J, Kang Y, Zhao R, *et al.* KrasG12D-induced IKK2/beta/NF-kappaB activation by IL-1alpha and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma. *Cancer Cell* 2012;21:105–20.
- Panarelli NC, Yantiss RK, Yeh MM, *et al.* Tissue-specific cadherin CDH17 is a useful marker of gastrointestinal adenocarcinomas with higher sensitivity than CDX2. *Am J Clin Pathol* 2012;138:211–22.
- Su MC, Yuan RH, Lin CY, *et al.* Cadherin-17 is a useful diagnostic marker for adenocarcinomas of the digestive system. *Mod Pathol* 2008;21:1379–86.
- Galgano MT, Hampton GM, Frierson HF Jr. Comprehensive analysis of HE4 expression in normal and malignant human tissues. *Mod Pathol* 2006;19:847–53.
- Takehara A, Hosokawa M, Eguchi H, *et al.* Gamma-aminobutyric acid (GABA) stimulates pancreatic cancer growth through overexpressing GABAA receptor pi subunit. *Cancer Res* 2007;67:9704–12.
- Ying H, Kimmelman AC, Lysiotis CA, *et al.* Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. *Cell* 2012;149:656–70.
- Rasheed ZA, Yang J, Wang Q, *et al.* Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. *J Natl Cancer Inst* 2010;102:340–51.
- Kahlert C, Bergmann F, Beck J, *et al.* Low expression of aldehyde dehydrogenase 1A1 (ALDH1A1) is a prognostic marker for poor survival in pancreatic cancer. *BMC Cancer* 2011;11:275.
- Mao P, Joshi K, Li J, *et al.* Mesenchymal glioma stem cells are maintained by activated glycolytic metabolism involving aldehyde dehydrogenase 1A3. *Proc Natl Acad Sci USA* 2013;110:8644–9.
- Mann KM, Ward JM, Yew CC, *et al.* Sleeping Beauty mutagenesis reveals cooperating mutations and pathways in pancreatic adenocarcinoma. *Proc Natl Acad Sci USA* 2012;109:5934–41.
- Perez-Mancera PA, Rust AG, van der Weyden L, *et al.* The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. *Nature* 2012;486:266–70.
- Weissmueller S, Manchado E, Saborowski M, *et al.* Mutant p53 drives pancreatic cancer metastasis through cell-autonomous PDGF receptor beta signaling. *Cell* 2014;157:382–94.
- Black W, Vasiliou V. The aldehyde dehydrogenase gene superfamily resource center. *Hum Genomics* 2009;4:136–42.
- Marcato P, Dean CA, Giacomantonio CA, *et al.* Aldehyde dehydrogenase: its role as a cancer stem cell marker comes down to the specific isoform. *Cell Cycle* 2011;10:1378–84.
- Rovira M, Scott SG, Liss AS, *et al.* Isolation and characterization of centroacinar/terminal ductal progenitor cells in adult mouse pancreas. *Proc Natl Acad Sci USA* 2010;107:75–80.
- Ioannou M, Serafimidis I, Arnes L, *et al.* ALDH1B1 is a potential stem/progenitor marker for multiple pancreas progenitor pools. *Dev Biol* 2013;374:153–63.
- Molotkov A, Molotkova N, Duester G. Retinoic acid generated by Raldh2 in mesoderm is required for mouse dorsal endodermal pancreas development. *Dev Dyn* 2005;232:950–7.



## A subset of metastatic pancreatic ductal adenocarcinomas depends quantitatively on oncogenic Kras/Mek/Erk-induced hyperactive mTOR signalling

Bo Kong, Weiwei Wu, Tao Cheng, Anna Melissa Schlitter, Chengjia Qian, Philipp Bruns, Ziyang Jian, Carsten Jäger, Ivonne Regel, Susanne Raulefs, Nora Behler, Martin Irmeler, Johannes Beckers, Helmut Friess, Mert Erkan, Jens T Siveke, Andrea Tannapfel, Stephan A Hahn, Fabian J Theis, Irene Esposito, Jörg Kleeff and Christoph W Michalski

*Gut* published online January 19, 2015

---

Updated information and services can be found at:  
<http://gut.bmj.com/content/early/2015/01/19/gutjnl-2014-307616>

---

### Supplementary Material

Supplementary material can be found at:  
<http://gut.bmj.com/content/suppl/2015/01/19/gutjnl-2014-307616.DC1.html>

*These include:*

### References

This article cites 38 articles, 13 of which you can access for free at:  
<http://gut.bmj.com/content/early/2015/01/19/gutjnl-2014-307616#BIBL>

### Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

---

### Topic Collections

Articles on similar topics can be found in the following collections

[Pancreas and biliary tract \(1905\)](#)

---

### Notes

---

To request permissions go to:  
<http://group.bmj.com/group/rights-licensing/permissions>

To order reprints go to:  
<http://journals.bmj.com/cgi/reprintform>

To subscribe to BMJ go to:  
<http://group.bmj.com/subscribe/>